THE HAGUE, The Netherlands, September 11, 2017 /PRNewswire/ — In the presence of former UN-Secretary-General Kofi Annan and Dutch minister Melanie Schultz of Infrastructure & the Environment, Micreos’ alternative to antibiotics was chosen as the most impactful innovation of The Netherlands. Micreos will represent The Netherlands at the semi-finals of Ideas from Europe in Talinn, Estonia […]

TARRYTOWN, N.Y. and PARIS, Sept. 8, 2017 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC, […]

Data presented at ESMO has demonstrated that a new blood test from Roche, co-developed with Foundation Medicine, can accurately measure the number of mutations within a tumour, which may help doctors to know which patients respond best to certain immunotherapies. Tumour mutational burden (TMB) is a quantitative clinical marker that measures the number of mutations […]

The outlook brightened today for Bristol-Myers Squibb’s Opdivo as combo med as the drugmaker released more results from a test of its Opdivo-plus-Yervoy combination as a first-line treatment in kidney cancer. The overall survival results were promising enough that BMS stopped the trial early. Today’s report led one analyst to predict “a very high likelihood […]

What’s Hot at ESMO 2017?
September 7, 2017

MADRID — The revolution in cancer therapy represented by targeted therapy and immunotherapy will be continued at Europe’s leading oncology meeting, when new data will show that the drugs are effective not only in the palliative setting but also in earlier stages of the disease. The European Society for Medical Oncology (ESMO) 2017 Congress, which […]

KENILWORTH, N.J. & MUNICH–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Rigontec today announced that Merck will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both […]

After winning an FDA approval for Exondys51 as a new therapy for Duchenne muscular dystrophy without having to actually produce data to prove it worked, Sarepta followed up this new morning with a fresh set of data from a small study underscoring the ability of its experimental followup exon-skipping drug golodirsen to trigger added production […]

Key FDA Regulatory Events to Watch Out for in Sep 2017
September 5, 2017

The FDA, which approved 22 novel drugs last year, has given its approval to 31 drugs so far in 2017 including five in August. Key approvals this year include Gilead’s Vosevi (hepatitis C virus), Puma’s Nerlynx (to reduce the risk of breast cancer returning), J&J’s Tremfya (moderate-to-severe plaque psoriasis), Regeneron/Sanofi’s Kevzara (rheumatoid arthritis), Roche’s multiple […]